BR96 DOXORUBICIN CONJUGATE VS DOXORUBICIN IN METASTATIC BREAST CANCER

BR96 多柔比星结合物与多柔比星在转移性乳腺癌中的比较

• 批准号: 6274063
• 负责人: MANSOOR N SALEH
• 金额: $ 2.59万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-01-26 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274063
• 关键词: breast neoplasms; clinical research; combination cancer therapy; doxorubicin; drug screening /evaluation; female; human subject; human therapy evaluation; immunoconjugates; metastasis; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; pharmacokinetics; women's health

This is a phase II trial comparing delivery of the agent doxorubicin either as an immunoconjugate linked to the monoclonal anti-Lewis(y) antibody BR96 or delivered as intravenous single injection of the de novo chemotherapy. BR96 doxorubicin has been shown to be well tolerated in a previous phase I study, and animal studies have demonstrated dramatic anti-tumor effects in breast tumor xenograft. The study aims to compare ability of BR96-doxorubicin to deliver cytoxic levels of doxorubicin to the tumor, as compared to single-agent doxorubicin, and assess the corresponding clinical outcome.

这是一项比较阿霉素制剂释放情况的II期试验。 或者作为连接到抗Lewis(Y)的单抗的免疫结合物 抗体BR96或静脉单次注射从头注射 化疗。BR96多柔比星已被证明在一种 之前的第一阶段研究和动物研究证明了戏剧性 乳腺肿瘤异种移植的抗肿瘤作用。这项研究旨在比较 BR96-阿霉素将细胞毒水平的阿霉素输送到细胞内的能力 肿瘤，与单药阿霉素相比，并评估 相应的临床结果。